Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Coagulation factor VIII (encoded by F8) is a multidomain glycoprotein essential for intrinsic tenase complex assembly. Mild hemophilia A is defined by factor VIII coagulant activity (FVIII:C) between 5% and 40% of normal and often presents with discrepant one-stage versus two-stage or chromogenic assay results ([PMID:10554831]).
F8-related mild hemophilia A follows an X-linked recessive inheritance pattern, with hemizygous males affected and heterozygous females usually asymptomatic or mildly deficient. Rare Turner syndrome cases reveal apparent homozygosity for F8 missense variants manifesting as mild FVIII deficiency masked by standard one-stage assays ([PMID:21707934]).
A spectrum of missense variants has been identified in mild hemophilia A. Notable examples include p.His1954Leu in the A3 domain disrupting assay concordance, p.Arg1708His (c.5123G>A (p.Arg1708His)) in exon 14 associated with mild deficiency, and p.Arg2182His recurring independently in three unrelated families with variable severity ([PMID:10215414]).
Segregation analysis of p.Arg2182His demonstrated co-segregation with mild to moderate bleeding phenotypes across three kindreds (totaling five affected males), supporting the variant’s pathogenicity and X-linked transmission ([PMID:10215414]).
Functional studies reveal that many mild hemophilia A variants accelerate A2 subunit dissociation from activated FVIII heterotrimer, reducing two-stage activity, while C-domain mutations impair von Willebrand factor binding and secretion. Structural modeling and in vitro assays consistently show impaired FIXa interaction and reduced proteolytic activation, aligning with clinical assay discrepancies ([PMID:9864159]).
Clinical utility of these findings underscores the need for combined one-stage and chromogenic assays when evaluating suspected mild hemophilia A. F8 sequencing confirms diagnosis, informs carrier status, and guides therapeutic management in patients with assay-discordant FVIII activity.
Gene–Disease AssociationDefinitive
Genetic EvidenceStrongMissense variants in multiple domains identified in >20 probands; recurrence in three families; X-linked segregation Functional EvidenceStrongBiochemical and modeling studies demonstrating consistent mechanism of A2 dissociation, vWF binding defects, and impaired activation across variants |